$CTAS

UBS maintains Buy on Cintas, raises target to $230

UBS analyst Joshua Chan maintained a Buy rating on Cintas (CTAS) and raised the price target to $230 from $228, citing an updated valuation outlook. The new target suggests potential upside from current trading levels.

Original reporting
Published Sep 16, 2026, 2:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 4:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Buy on Cintas, raises target to $230 — source image
Decision brief

The 30-second read

$CTASBullishLow
01

Why it matters

The incremental target increase signals modest confidence but offers limited trading edge.

02

Market read

Small analyst target tweak with minimal immediate market impact.

03

What to watch

Potential upcoming earnings or contract news could outweigh the modest target change.

Relevance 5/10Novelty 4/10Timing: Sep 16, 2026 (same‑day release)

Background

UBS analyst maintains Buy rating on Cintas, adjusting target slightly upward.

Company-level read

Ticker impact

$CTASBullishMedium confidence
Context

UBS raised Cintas price target to $230 from $228, maintaining a Buy rating.

Expected impact

Small upside pressure; price may test $230 level.

Evidence & confidence

Target raise is minor ($2) and reflects incremental valuation, unlikely to trigger large moves.

Market effects

Minor positive signal for industrial services sector.

Limited to U.S. equities; no broader regional effect.

Negligible.

Counterpoint

Target raise is too small to justify buying; price may already reflect the outlook.

Key entities

  • Cintas

    Industrial services provider (NASDAQ: CTAS).

  • UBS

    Investment bank providing equity research.

Related articles

$CTASHighAI 8/10

Wells Fargo maintains Overweight on Cintas, raises target to $250

Cintas reported Q4 2026 revenue of $2.91B, up 8.9%, and EPS of $1.29, beating estimates. Full-year revenue was $11.26B, up 8.9%. The company guided fiscal 2027 revenue to $12.1B-$12.25B and EPS to $5.36-$5.50. Wells Fargo raised its target to $250, and other analysts also increased price targets. Shares rose 2.9% in pre-market trading.

$CTASMed

Cintas-UniFirst deal spread widens on FTC scrutiny: Bernstein

Bernstein notes increased market concern over Cintas's (CTAS) acquisition of UniFirst (UNF) due to FTC scrutiny. The spread between the two stocks has widened, with UniFirst shares dropping 7% and Cintas down 2% since August 25. Analyst Connor Cerniglia rates Cintas Market Perform with a $200 price target, citing a 30% chance of deal failure. Cintas expects to complete its FTC response by November, with Bernstein believing the deal will likely close in early 2027.

$CTASMed

RBC Thinks Cintas Has Room To Raise Its Outlook

RBC raised Cintas' EPS forecast to $5.40-$5.55 and increased its revenue range, citing easier comparisons and solid execution. However, RBC noted fuel costs as a potential pressure and maintained a 'sector perform' rating and $206 price target, suggesting limited upside without improved profitability.

$VMed

Donald Trump makes over 1,000 securities trades in June, buys Berkshire Hathaway, Visa, Mastercard, and Cintas

Donald Trump's June financial disclosure shows 1,051 trades, with purchases exceeding $49M and sales of at least $28.5M. Notable buys include Berkshire Hathaway, Visa, Mastercard, and Cintas, while Meta Platforms and Motorola were sold. The largest transaction was a $5M-$25M sale of VIG ETF. Trump's accounts made 21,000 trades in 2025, managed by his children. The June 18 trades followed a market selloff triggered by a Federal Reserve meeting.

$CTASMed

Cintas (CTAS) Could Be 3% Below Fair Value After Strong Results And Guidance

Simply Wall St reports Cintas (CTAS) posted higher Q4 and full-year sales, revenue, and net income, and issued fiscal 2027 revenue guidance of US$12.10b to US$12.25b. The stock rose after results, trading at about US$205.91 versus a fair value estimate near US$212.41, implying roughly 3% undervaluation, with valuation risks tied to uniform demand and margins.